The Institute of Cancer Research, London, is one of the world’s most influential cancer research organisations. Today, find out how we topped the table in REF 2014, read our researchers' predictions for 2015, and hear about our Liver Cancer Appeal.
Earlier licensing could speed progress and reduce drug costs, say global experts including the ICR’s Professor Paul Workman.
A pioneering clinical trial is testing whether focusing high-frequency sound waves onto the surface of bone where cancer has spread can burn away the source of pain.
Major study has uncovered several new genetic mutations that could drive testicular cancer – and also identified a gene which may contribute to tumours becoming resistant.
Our Development Office is here to help you support our work, however you choose to do so
Dr Chris Bakal is doing fundamental research into cancer – vital to finding new ways of attacking it.
Dr Angela Kukula works with pharmaceutical companies to help develop new cancer drugs, using her expertise to negotiate collaborations between the ICR and industry
Our PhD students make a real contribution to defeating cancer while working full-time in the lab
We run clinical trials with The Royal Marsden – taking our lab results right to the bedside
Teams of biologists, chemists and computational scientists design new drugs to selectively attack tumours
Our PhD students conduct world-class research projects, while our MSc in Clinical Oncology teaches about the latest in clinical practice.
Our Chief Executive and President, Professor Paul Workman, shares his experiences on his blog, The Drug Discoverer.
The ICR’s research aims to learn more about cancer genetics and tumour biology – and use that information in discovering new treatments.
Your support can help us fight an often overlooked form of cancer, one that claims an increasingly large number of lives every year.
We work in close partnership with industry to take results into the clinic as soon as possible, and make sure our research delivers for cancer patients.
The ICR has an outstanding record of scientific achievement dating back more than 100 years. Read more about the ICR’s most influential discoveries.
Cancer drugs should be licensed on smaller trials to cut prices, global experts say http://t.co/BjuTAto3BI
Targeted treatments, big data and the pros and cons of having your genome sequenced
3D assays, genetic tests going mainstream and new ‘epigenetic’ drugs – ICR researchers gaze into their crystal balls
Huge team effort on REF is rewarded by a fantastic result and memorable week